Merck, Inc.
A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005)
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06647628
- Locations
- 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale Beach, Florida, United States
A Study of MK-2225 in Healthy Participants (MK-2225-003)
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06643390
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, LLC dba QPS-MO (Site 0004), Springfield, Missouri, United States
🇺🇸Clinical Pharmacology of Miami (Site 0002), Miami, Florida, United States
A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032)
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06643377
- Locations
- 🇺🇸
Nature Coast Clinical Research - Inverness ( Site 0002), Inverness, Florida, United States
🇺🇸Genesis Clinical Research, LLC ( Site 0001), Tampa, Florida, United States
🇺🇸Velocity Clinical Research, Hallandale Beach ( Site 0006), Hallandale Beach, Florida, United States
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06637423
A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06633419
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 170
- Registration Number
- NCT06630117
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0006), South Miami, Florida, United States
🇺🇸California Clinical Trials Medical Group managed by PAREXEL (Site 0002), Glendale, California, United States
🇺🇸Velocity Clinical Research, Hallandale Beach (Site 0003), Hallandale Beach, Florida, United States
A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06625827
- Locations
- 🇺🇸
ICON (Site 0001), Lenexa, Kansas, United States
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06625840
- Locations
- 🇺🇸
California Clinical Trials Medical Group managed by PAREXEL-PAREXEL International (Site 0001), Glendale, California, United States
A Study of Levothyroxine and Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-028)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT06625814
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Study of MK-8189 Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6
- Registration Number
- NCT06626464
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Madison, Wisconsin, United States